JPMA gives guidance on new flu type
The Japan Pharmaceutical Manufacturers Association has compiled handling and action guidelines of the new type of human influenza which is caused by the H5N1 virus, in a attempt to prepare for a potential pandemic.
The JPMA said its action guidance is aimed at helping drug companies to manufacture and produce pharmaceutical products, including flu vaccines, in a continuous and stable manner in the event of a flu pandemic.
Its move follows the Ministry of Health, Labor and Welfare's establishment of its Action Plan for Countermeasures against a New Type of Influenza in 2005 and its Guidelines for Countermeasures against a New Type of Influenza in March 2007, as well as a revision of the former in October 2007.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze